Researchers used a modular sequence of copper-catalyzed azide–alkyne cycloaddition (CuAAC), sulfur (VI) fluoride exchange (SuFEx), and Michael addition reactions to quickly assemble ...

Targeted protein degradation, which is a strategy to destroy cancer-causing proteins, has emerged in recent years as one of the hottest fields in drug discovery. Small molecules known as ...

Traditional drug research has focused on creating inhibitors that occupy the active areas of disease-related proteins, preventing them from functioning properly. But this strategy leaves a ...

The oncology market for PROTACs is projected to reach $3.7 billion by 2030, even though there are no FDA approved therapies currently. Protein homeostasis is critical for physiology of cell and their ...

Proteolysis-targeting chimeras (PROTACs), particularly those incorporating the von Hippel–Lindau (VHL) E3 ligase ligand, present significant physicochemical challenges due to their large molecular ...